FCER2 and B-cell chronic lymphocytic leukemia: However, 7%–20% of CLL patients are negative for CD5,16, 17 and 16% of CLL patients were CD23 dim,18 which may lead to decreased sensitivity as CD5 and CD23 were the positive markers in both Moreau and CLLflow score.